Cellectar Biosciences

Cellectar, Inc closed a reverse merger with the publicly-owned Novelos Therapeutics , Inc. (NVLT) (Press Release April 11, 2011) and will assume the Novelos name. Headquarters will remain in Madison, WI. Novelos will continue to develop Cellectar’s three novel cancer-targeted compounds – designated HOT, COLD and LIGHT – which are selectively taken up and retained in cancer cells, including cancer stem cells.